TheranosticTrials.org

Clinical Trial · NCT03009318

MRS and 11C-methionine PET/CT in the Diagnosis of Glioma

Overview

MET PET and MRS are often performed as imaging tool for the differential diagnosis of gliomas. But both techniques have limitations causing misdiagnosis; thus, the investigators tried to combine these two imaging tools to study whether the combination of MET PET and MRS could raise the diagnosis ability of the radiological diagnosis of gliomas.

Sponsor

Huashan Hospital

Phase

N/A

Contacts

Dongxiao Zhuang, Professor (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03009318

Drug / Compound

Methionine

Isotope(s):
Target(s):
  • Amino Acid Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Patients with non-enhancing supratentorial lesions shown by contrast-enhanced MRI
  • No surgery, chemotherapy or radiotherapy history

Exclusion

  • Primary gliomas with history of radiotherapy or chemotherapy
  • Patients with enhancing supratentorial lesions
  • Patients with infratentorial Neoplasms
  • Recurrent gliomas after surgery
  • History of malignant tumours at any body site